Pacira down 25% as FDA approves generic version of Exparel

Stock Market Down — jmiks

Pacira BioSciences (NASDAQ:PCRX) plummeted ~25% in Tuesday trading after the U.S. FDA approved a generic version of Exparel (bupivacaine liposome), a non-opioid used for post-surgery local anasthesia.
The agency approved an abbreviated New Drug Application for a generic version from Hengrui Pharma.
Exparel is by far Pacira’s biggest revenue driver. In Q1, it brought in $132M in revenue.

More on Pacira BioSciences

Previous Post: Job openings and labor turnover powers past consensus

Next Post: TotalEnergies plans to exit gas finds offshore South Africa – Bloomberg (NYSE:TTE)